JP7728265B2 - 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン - Google Patents
甲状腺ホルモン受容体アゴニストとしての置換トリアジノンInfo
- Publication number
- JP7728265B2 JP7728265B2 JP2022542655A JP2022542655A JP7728265B2 JP 7728265 B2 JP7728265 B2 JP 7728265B2 JP 2022542655 A JP2022542655 A JP 2022542655A JP 2022542655 A JP2022542655 A JP 2022542655A JP 7728265 B2 JP7728265 B2 JP 7728265B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- pharmaceutically acceptable
- present application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/071741 | 2020-01-13 | ||
| CN2020071741 | 2020-01-13 | ||
| CNPCT/CN2020/107757 | 2020-08-07 | ||
| CN2020107757 | 2020-08-07 | ||
| PCT/CN2021/071381 WO2021143706A1 (en) | 2020-01-13 | 2021-01-13 | Substituted triazinones as thyroid hormone receptor agonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023510835A JP2023510835A (ja) | 2023-03-15 |
| JP2023510835A5 JP2023510835A5 (https=) | 2024-01-25 |
| JPWO2021143706A5 JPWO2021143706A5 (https=) | 2024-01-25 |
| JP7728265B2 true JP7728265B2 (ja) | 2025-08-22 |
Family
ID=74418122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542655A Active JP7728265B2 (ja) | 2020-01-13 | 2021-01-13 | 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11780825B2 (https=) |
| EP (1) | EP4090652A1 (https=) |
| JP (1) | JP7728265B2 (https=) |
| KR (1) | KR20220128383A (https=) |
| CN (1) | CN115244037B (https=) |
| AU (1) | AU2021208027B2 (https=) |
| IL (1) | IL294494A (https=) |
| MX (1) | MX2022008626A (https=) |
| WO (1) | WO2021143706A1 (https=) |
| ZA (1) | ZA202207541B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| EP4090652A1 (en) | 2020-01-13 | 2022-11-23 | Eccogene (Shanghai) Co., Ltd. | Substituted triazinones as thyroid hormone receptor agonists |
| JP7813730B2 (ja) | 2020-06-17 | 2026-02-13 | オートバーン セラピューティクス，インク． | 甲状腺様作用剤 |
| WO2021257851A1 (en) | 2020-06-17 | 2021-12-23 | Autobahn Therapeutics, Inc. | Thyromimetics |
| EP4240730A1 (en) | 2020-11-06 | 2023-09-13 | Aligos Therapeutics, Inc. | 2-pyridones as thyroid hormone receptor modulators |
| CN114685450A (zh) * | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
| CN117624069A (zh) * | 2022-08-19 | 2024-03-01 | 凯思凯迪（上海）医药科技有限公司 | 一种多环类甲状腺激素β受体激动剂及其用途 |
| CN118146123A (zh) * | 2024-02-04 | 2024-06-07 | 河北鼎泰制药有限公司 | 一种盐酸安罗替尼中间体的合成方法 |
| WO2026067791A1 (en) * | 2024-09-30 | 2026-04-02 | Ascletis Pharma (China) Co., Limited | 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives as thr-beta agonist or modulators for the treatment of obesity |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012106996A (ja) | 2010-10-19 | 2012-06-07 | Mitsubishi Tanabe Pharma Corp | 新規甲状腺ホルモンβ受容体作動薬 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP1088819B1 (en) * | 1999-09-30 | 2005-06-15 | Pfizer Products Inc. | 6-azauracil derivatives as thyroid receptor ligands |
| DK1262177T3 (da) | 2001-05-31 | 2006-11-20 | Pfizer Prod Inc | Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner |
| PL1919878T3 (pl) | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| TWI534144B (zh) | 2009-04-20 | 2016-05-21 | 田邊三菱製藥股份有限公司 | 甲狀腺荷爾蒙β受體作動藥 |
| CN109574995B (zh) | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| CN111801324B (zh) | 2018-06-12 | 2021-10-22 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| EP4090652A1 (en) | 2020-01-13 | 2022-11-23 | Eccogene (Shanghai) Co., Ltd. | Substituted triazinones as thyroid hormone receptor agonists |
| JP7813730B2 (ja) * | 2020-06-17 | 2026-02-13 | オートバーン セラピューティクス，インク． | 甲状腺様作用剤 |
-
2021
- 2021-01-13 EP EP21702359.7A patent/EP4090652A1/en active Pending
- 2021-01-13 CN CN202180019696.0A patent/CN115244037B/zh active Active
- 2021-01-13 KR KR1020227027435A patent/KR20220128383A/ko active Pending
- 2021-01-13 AU AU2021208027A patent/AU2021208027B2/en active Active
- 2021-01-13 WO PCT/CN2021/071381 patent/WO2021143706A1/en not_active Ceased
- 2021-01-13 MX MX2022008626A patent/MX2022008626A/es unknown
- 2021-01-13 US US17/147,538 patent/US11780825B2/en active Active
- 2021-01-13 IL IL294494A patent/IL294494A/en unknown
- 2021-01-13 JP JP2022542655A patent/JP7728265B2/ja active Active
-
2022
- 2022-07-07 ZA ZA2022/07541A patent/ZA202207541B/en unknown
-
2023
- 2023-08-11 US US18/448,277 patent/US12291518B2/en active Active
-
2025
- 2025-03-03 US US19/068,129 patent/US20250320197A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012106996A (ja) | 2010-10-19 | 2012-06-07 | Mitsubishi Tanabe Pharma Corp | 新規甲状腺ホルモンβ受容体作動薬 |
Non-Patent Citations (3)
| Title |
|---|
| DANZI, S. et al.，Hormone and Metabolic Research，2011年，Vol. 43，No. 11，p. 737-742 |
| JOHARAPURKAR, Amit A. et al.，Journal of Medicinal Chemistry，2012年，Vol. 55，No. 12，p. 5649-5675 |
| LIU, Huanxiang et al，Bioorganic & Medicinal Chemistry，2007年，Vol. 15，No. 15，p. 5251-5261 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023510835A (ja) | 2023-03-15 |
| EP4090652A1 (en) | 2022-11-23 |
| CA3164404A1 (en) | 2021-07-22 |
| US12291518B2 (en) | 2025-05-06 |
| US20240190846A1 (en) | 2024-06-13 |
| US20250320197A1 (en) | 2025-10-16 |
| AU2021208027A1 (en) | 2022-07-28 |
| ZA202207541B (en) | 2024-12-18 |
| US20210230146A1 (en) | 2021-07-29 |
| IL294494A (en) | 2022-09-01 |
| KR20220128383A (ko) | 2022-09-20 |
| WO2021143706A1 (en) | 2021-07-22 |
| CN115244037B (zh) | 2024-10-25 |
| AU2021208027B2 (en) | 2025-10-16 |
| US11780825B2 (en) | 2023-10-10 |
| CN115244037A (zh) | 2022-10-25 |
| MX2022008626A (es) | 2022-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7728265B2 (ja) | 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン | |
| JP7569443B2 (ja) | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 | |
| JP7811578B2 (ja) | 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 | |
| WO2023029380A1 (zh) | 作为glp1r激动剂的新型芳醚取代杂环类化合物 | |
| CN110461830B (zh) | Jak1选择性抑制剂 | |
| CN114478497A (zh) | 芳基烷基酸类glp-1受体激动剂及其用途 | |
| CN104066729A (zh) | 溶血磷脂酸受体拮抗剂 | |
| WO2020147739A1 (zh) | 溶血磷脂酸受体拮抗剂及其制备方法 | |
| CN104093705A (zh) | 新的氮杂环丁烷衍生物、其药物组合物及其用途 | |
| CN108863850B (zh) | 联芳基类化合物及其制备方法和用途 | |
| CN104903296A (zh) | 二氢吡唑gpr40调节剂 | |
| CN115413279A (zh) | P2x3调节剂 | |
| TW201609734A (zh) | 用於治療寄生蟲疾病之化合物及組合物 | |
| TW201529557A (zh) | Ｃｘｃｒ７受體調節劑 | |
| WO2018145653A1 (zh) | 联芳基类化合物及其制备方法和用途 | |
| KR102734880B1 (ko) | 항바이러스 활성을 갖는 아마이드 유도체 | |
| JP7703272B2 (ja) | Ｓｓａｏ阻害剤およびその使用 | |
| WO2022033303A1 (zh) | 苄胺类衍生物及其制备方法与用途 | |
| CA3164404C (en) | Thyroid hormone receptor agonists and uses thereof | |
| CN111372928A (zh) | 用作钾通道抑制剂的苯并咪唑衍生物 | |
| CN109206360A (zh) | 咔唑酰胺类衍生物或其盐及其制备方法和用途 | |
| WO2025252247A1 (zh) | Gspt1降解剂抗体偶联物 | |
| EP3380455A1 (en) | Trypanosomes inhibitors | |
| HK40127587A (zh) | Pcsk9抑制剂及其使用方法 | |
| WO2025236565A1 (zh) | 杂环烷基羧酸衍生物、中间体及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241219 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250529 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20250530 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250731 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250812 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7728265 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |